Related Experiment Videos
Amrinone reverses bupivacaine-induced regional myocardial dysfunction
1Department of Anesthesiology, Kawasaki Medical School, Kurashiki-City, Okayama, Japan.
Acta Anaesthesiologica Scandinavica
|January 1, 1996
Summary
Amrinone effectively reversed bupivacaine-induced heart dysfunction in dogs. This study shows amrinone's therapeutic potential in treating bupivacaine cardiotoxicity by restoring regional myocardial function.
Area of Science:
- Cardiology
- Pharmacology
- Cardiovascular Toxicology
Background:
- Bupivacaine can cause severe cardiovascular toxicity.
- Amrinone has shown therapeutic potential against bupivacaine toxicity.
- The precise cardiac effects of amrinone in this context require further investigation.
Purpose of the Study:
- To evaluate the regional myocardial effects of amrinone on bupivacaine-induced cardiovascular toxicity.
- To understand how amrinone influences cardiac function during bupivacaine toxicity.
Main Methods:
- Utilized an in situ beating heart model in 10 dogs.
- Employed selective coronary perfusion and sonomicrometry to assess regional myocardial function.
- Administered bupivacaine to the left anterior descending coronary artery (LAD) incrementally, with or without amrinone co-infusion.
Main Results:
- Bupivacaine dose-dependently decreased systolic shortening and increased post-systolic shortening in the LAD-perfused region.
- Amrinone co-infusion at higher bupivacaine concentrations restored systolic shortening and post-systolic shortening to near baseline levels.
- Demonstrated a reversal of bupivacaine-induced regional myocardial dysfunction by amrinone.
Conclusions:
- Amrinone effectively reverses bupivacaine-induced regional myocardial dysfunction.
- These findings suggest amrinone's therapeutic efficacy in managing bupivacaine cardiotoxicity.
- Further research into amrinone's cardioprotective mechanisms is warranted.